Merck halts nemtabrutinib development after trial review flags unfavorable risk-benefit profile
- Merck is discontinuing its entire BELLWAVE clinical development program for nemtabrutinib, an investigational treatment for blood cancers.
- A review of Phase 3 BELLWAVE-011 data confirmed the treatment's benefits may not outweigh its risks.
- The decision also ends Phase 3 trials BELLWAVE-008 and BELLWAVE-010.
- Trial data analyses remain ongoing; results will be shared with the scientific community.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Merck & Co. Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202611171615BIZWIRE_USPR_____20261117_BW906556) on November 17, 2026, and is solely responsible for the information contained therein.